Companion Diagnostic Technologies Market Global Report 2026

The companion diagnostic technologies market size has grown rapidly in recent years. It will grow from $4.44 billion in 2025 to $4.97 billion in 2026 at a compound annual growth rate (CAGR) of 12%. The growth in the historic period can be attributed to growth in precision medicine adoption, rising prevalence of cancer and chronic diseases, increasing demand for targeted therapeutic solutions, expansion of molecular diagnostics research activities, growing investment in biomarker discovery programs.

The companion diagnostic technologies market size is expected to see rapid growth in the next few years. It will grow to $7.89 billion in 2030 at a compound annual growth rate (CAGR) of 12.2%. The growth in the forecast period can be attributed to rising development of personalized treatment regimens, increasing adoption of AI enabled diagnostic interpretation platforms, growing demand for non invasive liquid biopsy diagnostics, expansion of pharmaceutical and diagnostic company collaborations, increasing regulatory approvals for companion diagnostic assays. Major trends in the forecast period include increasing adoption of biomarker based targeted therapy selection, rising demand for next generation sequencing companion diagnostics, growing use of liquid biopsy testing solutions, expansion of personalized oncology treatment approaches, increasing integration of multiplex molecular diagnostic testing.

The increasing demand for targeted therapies is expected to propel the growth of the companion diagnostic technologies market going forward. Targeted therapies refer to a form of medical treatment that uses drugs or other substances to precisely identify and attack specific cancer cells or molecular targets, minimizing damage to healthy cells. The demand for targeted therapies is rising due to their ability to precisely attack disease-specific pathways, resulting in improved efficacy with fewer side effects. Companion diagnostic technologies support targeted therapies by enabling the identification of specific genetic mutations, biomarkers, and molecular profiles, thereby helping in selecting the most effective targeted treatment for individual patients, improving treatment accuracy, and enhancing clinical decision-making in oncology and other disease areas. For instance, in July 2023, according to the report published by the American Society of Gene & Cell Therapy (ASGCT), a US-based professional membership organization, at the end of the first quarter (Q1) 2023, there were 247 gene therapies in Phase II, but this number rose by 5% to reach 260 by the end of the second quarter(Q2). Therefore, the increasing demand for targeted therapies is driving the growth of the companion diagnostic technologies market.

Major companies operating in the companion diagnostic technologies market are focusing on developing advanced genomic testing solutions, such as liquid biopsy-based companion diagnostics, to enhance precision medicine, improve targeted therapy selection, and enable more accurate cancer treatment decision-making. Liquid biopsy-based companion diagnostics refer to blood- or fluid-based tests used to detect specific biomarkers that guide and match patients to appropriate targeted therapies. For instance, in October 2024, Foundation Medicine, Inc., a US-based molecular information company, announced the Food and Drug Administration (FDA) approved its Liquid CDx test in combination with Itovebi, strengthening its role in precision oncology diagnostics. The solution is made to help doctors choose better treatments and make clinical decisions by using a blood test that looks at a wide range of genes, which helps them find important mutations and direct cancer treatments more effectively.

In September 2025, Lunit, a South Korea-based provider of AI-powered digital pathology and imaging tools, collaborated with Agilent Technologies Inc. to accelerate precision medicine through AI-powered companion diagnostics. The partnership aims to integrate Lunit’s AI-driven cancer analysis with Agilent Technologies’ diagnostic and genomics capabilities to develop more accurate and efficient companion diagnostic solutions for targeted therapies. Agilent Technologies Inc. is a US-based company that specializes in the development and commercialization of companion diagnostics (CDx).

Major companies operating in the companion diagnostic technologies market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Siemens Healthineers AG, Danaher Corporation, Becton Dickinson and Company, BioGenex Laboratories Inc., Quest Diagnostics Incorporated, Agilent Technologies Inc., Illumina Inc., bioMérieux S. A., Shimadzu Corporation, Sysmex Corporation, Bio-Rad Laboratories Inc., QIAGEN N. V., DiaSorin S. p. A., Caris Life Sciences Inc., Myriad Genetics Inc., Servier Laboratories, Pillar Biosciences Inc., EntroGen Inc.

North America was the largest region in the companion diagnostic technologies market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the companion diagnostic technologies market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the companion diagnostic technologies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The companion diagnostic technologies market consists of revenues earned by entities by providing services such as patient stratification for targeted therapies, biomarker validation support, therapy response monitoring, and clinical trial enrichment. The market value includes the value of related goods sold by the service provider or included within the service offering. The companion diagnostic technologies market also includes sales of consumable test strips, staining reagent kits, and nucleic acid extraction kits. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.